Dicerna's approach offers strong advantages over conventional RNAi
ABOUT DICERNA PHARMACEUTICALS
Dicerna Pharmaceuticals is developing next generation RNA interference (RNAi) therapeutics in multiple disease areas, based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules. Learn more.
NEWS & EVENTS
04 Apr 2012
Dicerna Honored Among Five of New England's Emerging Biotech Stars at Xconomy Forum
04 Jan 2012
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer (PDF)
15 Dec 2011
Dicerna Pharmaceuticals Announces First DsiRNA Therapeutic Candidate Selected for Development, Triggering $5 Million Milestone Payment (PDF)